文献速递肝病

MASLD无创检测生物标志物的可重复性:临床有意义变化的基准

Reproducibility of biomarkers in MASLD: A benchmark for clinically meaningful change in serially measured non-invasive tests.
PubMed 文献 · J Hepatol · 2026-08-03

本研究在11国198个中心的对活检确诊的高风险MASLD患者进行二期临床试验筛查,评估多种无创检测的测量变异。结果显示ELF的重复性最佳(wCV 3.4%,RDC 9.3%),LSM-VCTE的wCV为19.9%、RDC为55.2%,为临床纵向监测和试验疗效评估提供了可重复性基准。

要点

  • ELF在MASLD无创检测中重复性最佳,wCV 3.4%、RDC 9.3%。
  • LSM-VCTE的测量变异较大,筛查集wCV 19.9%、RDC 55.2%。
  • CAP在FibroScan参数中变异最低,筛查集wCV 8.8%、RDC 24.2%。

核心结论

  • 多种常用无创检测的可重复性数据可为临床纵向监测疾病进展和试验疗效评估提供生物学意义变化的参考。

研究设计与样本

  • 研究在11个国家198个中心开展,筛查分析集803例,随机分析集255例,均为活检确诊的高风险MASLD患者。

主要发现

  • LSM-VCTE在筛查分析集的wCV为19.9%、RDC为55.2%,在随机分析集分别为23.0%和63.8%。
  • CAP在筛查分析集的wCV为8.8%、RDC为24.2%,在随机分析集分别为8.7%和24.1%。
  • ELF总体wCV最低为3.4%,RDC最低为9.3%。

临床怎么用

  • 临床纵向监测MASLD患者时,应参考各无创检测的wCV和RDC判断生物标志物变化是否超出测量变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The use of non-invasive tests (NITs) to monitor disease severity in metabolic dysfunction-associated steatotic liver disease (MASLD) necessitates a clear understanding of clinically meaningful changes at the patient level. This study assessed the measurement variation of NITs in the pre-randomisation screening pipeline of a phase II clinical trial in patients with biopsy-confirmed at-risk MASLD. METHODS: This study was conducted across 198 centres in 11 countries. The screening analysis set (ScrAS) (n = 803) comprised patients screened for trial entry with an evaluable biopsy for eligibility assessment. The randomised analysis set (RAS) (n = 255) comprised participants with histologically confirmed at-risk steatohepatitis that fulfilled all trial entry criteria and represents a more highly characterised subset nested within the larger ScrAS dataset. Multiple NITs (including vibration controlled transient elastography [LSM-VCTE], enhanced liver fibrosis test [ELF], PRO-C3, ADAPT, PRO-C6, CK-18 M30/M65) were evaluated for measurement variation, with results reported as within-subject % coefficient of variation (wCV) and reproducibility coefficient % (RDC). RESULTS: The analysis of ScrAS demonstrates that LSM-VCTE exhibits a wCV of 19.9%, with a corresponding RDC of 55.2%. LSM-VCTE in RAS shows a wCV of 23.0% and RDC of 63.8%. While controlled attenuation parameter had the lowest wCV (8.8% in ScrAS; 8.7% in RAS) and RDC (24.2% in ScrAS; 24.1% in RAS) of the FibroScan-derived parameters, ELF demonstrated the lowest wCV (3.4%) and RDC (9.3%) overall. CONCLUSIONS: These data provide a clear and robust measure of reproducibility for a range of widely adopted NITs, providing insights into the magnitude of biomarker change that may be biologically meaningful and thereby informing both longitudinal monitoring of disease progression in clinical practice and assessment of treatment response in therapeutic trials. CLINICALTRIALS: gov (NCT#04321031). IMPACT AND IMPLICATIONS: The lack of disease-specific biomarker reproducibility data has hampered the adoption of non-invasive tests (NITs) for longitudinal monitoring of disease natural history in clinical practice, and has hindered the regulatory adoption of NITs as tractable surrogate endpoints to support drug development, as it leads to uncertainty about what magnitude of biomarker change indicates genuine disease progression. The present study addresses both these challenges by providing a clear and robust measure of reproducibility for a range of widely adopted NITs, generating actionable data that facilitate longitudinal monitoring of disease progression and treatment response.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Au TY, Darekar A, Wong VW, et al. Reproducibility of biomarkers in MASLD: A benchmark for clinically meaningful change in serially measured non-invasive tests. J Hepatol. 2026. PMID: 42546879. doi:10.1016/j.jhep.2026.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。